• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Development and validation of an egg-based potency assay for a trivalent live attenuated influenza vaccine

tetano

Editor, Senior Moderator
Biologicals. 2012 Jan 21. [Epub ahead of print]
Development and validation of an egg-based potency assay for a trivalent live attenuated influenza vaccine.
Yeolekar LR, Dhere RM.
Source

Serum Institute of India Limited, 212/2 Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411028, India.
Abstract

Live attenuated influenza vaccines (LAIVs) targeting seasonal influenza are produced in embryonated eggs and formulated as a trivalent preparation of three live attenuated vaccine strains, one A(H1N1) strain, one A(H3N2) strain and one type B strain. In this study, we describe an egg-based potency assay for estimating the 50% Egg infectious dose (EID(50)) of individual strains in the trivalent preparation by selective neutralisation of two strains and then estimating the infective titres of the non-neutralised strain. The test is highly specific, and no cross interference of heterologous antisera is observed in the estimation of individual titres. Individual strains with titres in the range of 6.5-7.0 log EID(50) per 0.5 ml show intra-assay and inter-assay coefficients of variance ranging from 1.25% to 2.95%. This assay was developed to establish a simple, reliable and inexpensive egg-based assay for estimating the potency of individual strains in a trivalent preparation.

Copyright ? 2011 The International Alliance for Biologicals. Published by Elsevier Ltd. All rights reserved.

PMID:
22269606
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22269606
 
Back
Top Bottom